An Ethical Analysis of Pharmacy Benefit Manager (PBM) Practices

被引:4
|
作者
Drettwan, Jacob J. [1 ]
Kjos, Andrea L. [1 ]
机构
[1] Drake Univ, Coll Pharm & Hlth Sci, Des Moines, IA 50311 USA
来源
PHARMACY | 2019年 / 7卷 / 02期
关键词
pharmacy benefit manager (PBM); ethics; pharmaceutical regulation; health care policy; decision-making; organizations; ethical models; code of ethics; pharmacist; DECISION-MAKING; DRUGS; COST; PRESCRIPTION; POLICY;
D O I
10.3390/pharmacy7020065
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The high costs associated with pharmaceuticals and the accompanying stakeholders are being closely evaluated in the search for solutions. As a major stakeholder in the U.S. pharmaceutical market, the practices of pharmacy benefit manager (PBM) organizations have been under increased scrutiny. Examples of controversial practices have included incentives driving formulary status and prohibiting pharmacists from disclosing information on lower-cost prescription alternatives. Ethical investigations have been largely omitted within the debate on the responsibilities of these organizations in the health care system. Ethical analysis of organizational practices is justified based on the potential impact during health care delivery. The objective of this study was to analyze several specific PBM practices using multiple ethical decision-making models to determine their ethical nature. This study systematically applied multiple ethical decision-making models and codes of ethics to a variety of practices associated with PBM-related dilemmas encountered in the pharmaceutical environment. The assessed scenarios resulted in mixed outcomes. PBM practices were both ethical and unethical depending on the applied ethical model. Despite variation across applied models, some practices were predominately ethical or unethical. The point of sale rebates were consistently determined as ethical, whereas market consolidation, gag clauses, and fluctuation of pharmacy reimbursements were all predominantly determined as unethical. The application of using provider codes of ethics created additional comparison and also contained mixed findings. This study provided a unique assessment of PBM practices and provides context from a variety of ethical perspectives. To the knowledge of the authors, these perspectives have not been previously applied to PBM practices in the literature. The application of ethical decision-making models offers a unique context to current health care dilemmas. It is important to analyze health care dilemmas using ethics-based frameworks to contribute solutions addressing complexities and values of all stakeholders in the health care environment.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] UNDERSTANDING PHARMACY BENEFIT MANAGER (PBM) ADOPTION OF HUMIRA BIOSIMILARS AND IDENTIFYING THEIR PREFERRED HUMIRA BIOSIMILARS IN COMPARISON WITH HUMIRA
    Okorozo, P.
    Da, Conceicao R.
    Narvekar, P.
    Daniel, I
    VALUE IN HEALTH, 2024, 27 (06) : S199 - S199
  • [2] IMPACT OF A PHARMACY BENEFITS MANAGER (PBM) CLINICAL PROGRAM ON TRANSITIONS OF CARE
    Giunta, Elizabeth
    Cherian, Sheena
    Spina, Courtney
    Patel, Binal
    Herbst, Melanie
    RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY, 2019, 15 (06): : E27 - E28
  • [3] Undocumented source of pharmacy benefit manager revenue
    Siracuse, Mark V.
    Clark, Bartholomew E.
    Gams, Robert I.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2008, 65 (06) : 552 - 557
  • [4] Evolution of the Pharmacy Benefit Manager/Community Pharmacy Relationship: An Opportunity for Success
    Taddei-Allen, Patty
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (06): : 708 - 710
  • [5] Managed care and pharmacy benefit managers (PBM): A source of inspiration for France?
    Lancry, PJ
    REVUE FRANCAISE D ETUDES AMERICAINES, 1998, (77): : 38 - 45
  • [6] Pharmacy Benefit Manager Reform: Lessons From Ohio
    Royce, Trevor J.
    Kircher, Sheetal
    Conti, Rena M.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 322 (04): : 299 - 300
  • [7] THE FINANCIAL IMPACT OF A DAILY AVERAGE CONSUMPTION (DACON) ANALYSIS IN A US PHARMACY BENEFIT MANAGEMENT (PBM) COMPANY
    Rice, G.
    Carlton, R.
    Regan, T.
    VALUE IN HEALTH, 2010, 13 (03) : A218 - A219
  • [8] Prevalence of Comorbidity of Chronic Diseases: A South African Pharmacy Benefit Management Company (PBM) Database Analysis
    Rothmann, Lourens
    Lubbe, Martie S.
    Gerber, Jan J.
    Bekker, Anne-Marie
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 117 - 117
  • [9] User experiences with pharmacy benefit manager data at the point of care
    Kaushal, Rainu
    Dhopeshwarkar, Rina
    Gottlieb, Lawrence
    Jordan, Harmon
    JOURNAL OF EVALUATION IN CLINICAL PRACTICE, 2010, 16 (06) : 1076 - 1080
  • [10] Opportunities for depression disease management: A pharmacy benefit manager's experience
    Fulop, G
    Kelly, MA
    Robinson, D
    Brown, DR
    Carides, P
    Brookler, R
    Suppapanya, N
    DEPRESSION AND ANXIETY, 1999, 10 (02) : 61 - 67